TETRAX

biochemicals, namely, antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules for in vitro scientific or research use

pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical products for the diagnosis, prevention and treatment of cancer; Antibodies being pharmaceutical preparations for the diagnosis, treatment and prevention of cancer, immune response disorders, genetic conditions, infectious diseases and vascular diseases; Vaccines; Pharmaceutical preparations for cell therapy; Preparations of blood extracted from humans or animals which have been adapted for medical or therapeutic purposes

custom manufacture of therapeutic drugs, namely, custom manufacture of cell therapies and cancer therapies; Manufacture of pharmaceuticals, pharmaceutical ingredients, vaccines and antibodies for others

custom design and engineering of antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules; Providing a bioinformatics platform as a service (PAAS) featuring computer software for developing antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules; Custom design and engineering of antibodies; Custom design and engineering of antigens; Antibody engineering; Biochemical research and development; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Development and establishment of testing specifications and procedures in the field of biotechnology; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the development of new cancer therapies; Scientific research in human and animal cell therapy; Platform as a service (PAAS) featuring computer software platforms for analysis of bioinformatic data